retatrutide latest trial results Eli Lilly's Phase 3 Results: 28.7% Weight Loss | Drug Discovery & Development posted on the topic Retatrutide Severe Obesity Trial Shows

GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of alcohol in animal models but no reports exist on the latter

The body stores fat differently after menopause

In this highly crowded arena, which players are positioned to break out

In this review, we summarize the state-of-the-art evidence regarding the epidemiology and pathophysiology of diabetic HFpEF, and the landscape of the novel antidiabetic drugs in the treatment of diabetic HFpEF, as well as discuss the relevant mechanisms, aiming to broaden the understanding of diabetic HFpEF and gain new insight into the treatment of this disease

By promoting the growth of beneficial bacteria and supporting short-chain fatty acid (SCFA) production, GLP-Balance helps create a favorable environment for satiety, nutrient absorption, and weight management.*